C12Y 304/21
Serine endopeptidases
Official title: Serine endopeptidases (3.4.21)
C12Y304/21 (Serine endopeptidases) appears on 2,758 US grants and 4,075 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2,758
- Published applications
- 4,075
- Assignees
- 1,503
- Inventors
- 7,049
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 7 | 0 |
| 1977 | 7 | 0 |
| 1978 | 5 | 0 |
| 1979 | 6 | 0 |
| 1980 | 4 | 0 |
| 1981 | 15 | 0 |
| 1982 | 12 | 0 |
| 1983 | 7 | 0 |
| 1984 | 9 | 0 |
| 1985 | 15 | 0 |
| 1986 | 9 | 0 |
| 1987 | 11 | 0 |
| 1988 | 12 | 0 |
| 1989 | 11 | 0 |
| 1990 | 33 | 0 |
| 1991 | 39 | 0 |
| 1992 | 48 | 0 |
| 1993 | 46 | 0 |
| 1994 | 37 | 0 |
| 1995 | 34 | 0 |
| 1996 | 48 | 0 |
| 1997 | 61 | 0 |
| 1998 | 84 | 0 |
| 1999 | 72 | 0 |
| 2000 | 54 | 0 |
| 2001 | 47 | 10 |
| 2002 | 35 | 56 |
| 2003 | 46 | 102 |
| 2004 | 33 | 101 |
| 2005 | 32 | 70 |
| 2006 | 31 | 83 |
| 2007 | 28 | 63 |
| 2008 | 41 | 105 |
| 2009 | 29 | 101 |
| 2010 | 49 | 102 |
| 2011 | 50 | 115 |
| 2012 | 58 | 121 |
| 2013 | 56 | 122 |
| 2014 | 78 | 167 |
| 2015 | 107 | 220 |
| 2016 | 104 | 269 |
| 2017 | 125 | 264 |
| 2018 | 135 | 232 |
| 2019 | 147 | 269 |
| 2020 | 160 | 251 |
| 2021 | 157 | 225 |
| 2022 | 125 | 218 |
| 2023 | 101 | 233 |
| 2024 | 116 | 206 |
| 2025 | 111 | 197 |
| 2026 | 71 | 173 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 304/21069Protein c activated445
- C12Y 304/21022Coagulation factor ixa414
- C12Y 304/21005Thrombin329
- C12Y 304/21021Coagulation factor viia255
- C12Y 304/21062Subtilisin226
- C12Y 304/21073U-plasminogen activator , i.e. urokinase215
- C12Y 304/21007Plasmin , i.e. fibrinolysin211
- C12Y 304/21004Trypsin170
All 103 subgroupsShow fewer
- C12Y 304/21006Coagulation factor xa142
- C12Y 304/21068Tissue plasminogen activator , i.e. tpa106
- C12Y 304/21001Chymotrypsin79
- C12Y 304/21061Kexin , i.e. proprotein convertase subtilisin/kexin type 959
- C12Y 304/21026Prolyl oligopeptidase , i.e. proline-specific endopeptidase34
- C12Y 304/21027Coagulation factor xia34
- C12Y 304/21014Microbial serine proteases32
- C12Y 304/21064Peptidase k29
- C12Y 304/21047Alternative-complement-pathway c3/c5 convertase , i.e. properdin factor b23
- C12Y 304/21077Semenogelase , i.e. prostate specific antigen or psa or kallikrein 322
- C12Y 304/21109Matriptase22
- C12Y 304/21075Furin19
- C12Y 304/21009Enteropeptidase , i.e. enterokinase16
- C12Y 304/21034Plasma kallikrein16
- C12Y 304/21042Complement subcomponent c1s16
- C12Y 304/21104Mannan-binding lectin-associated serine protease-216
- C12Y 304/21098Hepacivirin14
- C12Y 304/21037Leukocyte elastase , i.e. neutrophil-elastase13
- C12Y 304/21043Classical-complement-pathway c3/c5 convertase13
- C12Y 304/21079Granzyme b13
- C12Y 304/21084Limulus clotting factor c13
- C12Y 304/21031Urokinase11
- C12Y 304/21036Pancreatic elastase10
- C12Y 304/21038Coagulation factor xiia10
- C12Y 304/21078Granzyme a10
- C12Y 304/21112Site-1 protease , i.e. subtilisin kexin isozyme-110
- C12Y 304/21063Oryzin8
- C12Y 304/2107Pancreatic endopeptidase e8
- C12Y 304/21035Tissue kallikrein7
- C12Y 304/21002Chymotrypsin c6
- C12Y 304/21046Complement factor d6
- C12Y 304/2105Lysyl endopeptidase6
- C12Y 304/21059Tryptase6
- C12Y 304/21111Aqualysin 16
- C12Y 304/21008Kallikrein5
- C12Y 304/2102Cathepsin g5
- C12Y 304/21048Cerevisin5
- C12Y 304/21019Glutamyl endopeptidase4
- C12Y 304/21039Chymase4
- C12Y 304/21085Limulus clotting factor b4
- C12Y 304/21092Endopeptidase clp4
- C12Y 304/2111C5a peptidase4
- C12Y 304/21057Leucyl endopeptidase3
- C12Y 304/21074Venombin a3
- C12Y 304/21118Kallikrein 83
- C12Y 304/21011Elastase2
- C12Y 304/21045Complement factor i2
- C12Y 304/21053Endopeptidase la2
- C12Y 304/21072Iga-specific serine endopeptidase2
- C12Y 304/2108Streptogrisin a2
- C12Y 304/21093Proprotein convertase 12
- C12Y 304/2101Acrosin1
- C12Y 304/21066Thermitase1
- C12Y 304/21067Endopeptidase so1
- C12Y 304/21076Myeloblastin1
- C12Y 304/21081Streptogrisin b1
- C12Y 304/21086Limulus clotting enzyme1
- C12Y 304/21089Signal peptidase i1
- C12Y 304/21096Lactocepin1
- C12Y 304/21102C-terminal processing peptidase1
- C12Y 304/21107Peptidase do1
- C12Y 304/21113Pestivirus ns3 polyprotein peptidase1
- C12Y 304/21003Metridin0
- C12Y 304/21012Alpha-lytic endopeptidase0
- C12Y 304/21025Cucumisin0
- C12Y 304/21032Brachyurin0
- C12Y 304/21041Complement subcomponent c1r0
- C12Y 304/21049Hypodermin c0
- C12Y 304/21054Gamma-renin0
- C12Y 304/21055Venombin ab0
- C12Y 304/2106Scutelarin0
- C12Y 304/21065Thermomycolin0
- C12Y 304/21071Pancreatic elastase ii0
- C12Y 304/21082Glutamyl endopeptidase ii0
- C12Y 304/21083Oligopeptidase b , i.e. trypsin-like protease0
- C12Y 304/21088Repressor lexa0
- C12Y 304/2109Togavirin0
- C12Y 304/21091Flavivirin0
- C12Y 304/21094Proprotein convertase 2 , i.e. prohormone convertase 20
- C12Y 304/21095Snake venom factor v activator0
- C12Y 304/21097Assemblin0
- C12Y 304/21099Spermosin0
- C12Y 304/211Sedolisin0
- C12Y 304/21101Xanthomonalisin0
- C12Y 304/21103Physarolisin , i.e. physaropepsin0
- C12Y 304/21105Rhomboid protease0
- C12Y 304/21106Hepsin0
- C12Y 304/21108Htra2 peptidase0
- C12Y 304/21114Equine arterivirus serine peptidase0
- C12Y 304/21115Infectious pancreatic necrosis birnavirus vp4 peptidase0
- C12Y 304/21116Spoivb peptidase0
- C12Y 304/21117Stratum corneum chymotryptic enzyme0
- C12Y 304/21119Kallikrein 130
- C12Y 304/2112Oviductin0
- C12Y 304/21826Proprotein convertase 50
Recent patents
- Cleaning compositions comprising dispersins VI29 Sep 2026US 12,747,416 B2Henkel AG & Co. KGaA
- Method for analyzing protein29 Sep 2026US 12,747,465 B2Hitachi, Ltd.
- Methods of treating ischemic disease by administering an ATR kinase inhibitor22 Sep 2026US 12,740,980 B2East Tennessee State University Research Foundation
- Complement factor I and complement factor I cofactor, vectors encoding therefor and therapeutic use8 Sep 2026US 12,728,171 B2Novartis Pharmaceuticals UK Limited
- Subtilisin variants and methods of use1 Sep 2026US 12,723,239 B2Danisco US Inc.
- Plasmin-induced internal limiting membrane digestion facilitates donor retinal ganglion cell transplantation8 Oct 2026US 2026/0306549 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Human factor vii deletion constructs for treating cancer8 Oct 2026US 2026/0306592 A1The Cleveland Clinic Foundation
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Method for the Production of Pharmaceutically Active Recombinant Human Low Molecular Weight Urokinase8 Oct 2026US 2026/0308654 A1Cerbios-Pharma SA
- Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a1 Oct 2026US 2026/0295022 A1KM Biologics Co., Ltd.
Most cited
By later US patents
- Plasminogen activator derivatives616US 4,640,835 ANippon Chemiphar Co., Ltd. · 1987
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Method for dominant selection in eucaryotic cells277US 5,122,464 ACelltech Limited, a British Company · 1992
- Hemostatic agent270US 4,655,211 AUnitika Ltd. · 1987